<DOC>
	<DOCNO>NCT00038012</DOCNO>
	<brief_summary>A Pilot Study Transfusion rhTPO-Derived Autologous Platelets Cryopreserved ThromboSol 2 % DMSO Patients Gynecologic Malignancy Receiving Carboplatin</brief_summary>
	<brief_title>rhTPO Mobilized Auto Cryo Platelets For GYN Patients Receiving Carboplatin</brief_title>
	<detailed_description />
	<mesh_term>Genital Neoplasms , Female</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients gynecologic malignancy treatment carboplatin indicate . Age &gt; /= 15 year . Adequate hematologic , renal , hepatic function . Life expectancy &gt; / 3 month . Karnofsky Performance Status &gt; /= 80 . Signed informed consent form . EXCLUSION CRITERIA : Patients rapidly progressive disease . Pregnant lactating woman . Patients comorbid condition render patient high risk treatment complication . History CNS metastasis . Patients significant cardiac disease ( NYHA Class III IV ) , dysrhythmia , recent history MI ischemia , transient ischemic attack CVA within 6 month study entry . Prior chemotherapy , immunotherapy , experimental drug within 4 week , use myeloid ( GCSF GMCSF ) growth factor within 2 week erythropoietin within 4 week . Use nitrosourea ( BCNU , CCNU ) mitomycin C within 6 week . Prior surgery RT within 2 wks study entry . Patients history prior high dose chemotherapy stem cell transplant history prolong thrombocytopenia ( &gt; 2 week ) . History leukemia . History platelet disorder include ITP , TTP bleed disorder . History &gt; 3 prior chemotherapy regimen ( platinum regimen count 1 regimen ) . Demonstrated lack response platinumbased therapy .</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Dose-intensified carboplatin</keyword>
	<keyword>autologous cryopreserved platelet</keyword>
	<keyword>thrombopoietin</keyword>
	<keyword>Gynecologic malignancy</keyword>
</DOC>